Treatment of refractory tardive dyskinesia with donepezil in an elderly patient with depression

Psychogeriatrics

Volumn 8, Issue 4, 2008, Pages 196-198

  Yoshimi, Asuka ^a   Togo, Takashi ^a   Sugiyama, Naoya ^a   Uehara, Kumi ^a   Otsuka, Tatsui ^a   Karashima, Aya ^a   Hirayasu, Yoshio ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Acetylcholinesterase; Donepezil; Involuntary movement; Oral dyskinesia; Tardive dyskinesia

Indexed keywords

AMOXAPINE; BENZODIAZEPINE DERIVATIVE; CLOMIPRAMINE; CLONAZEPAM; DONEPEZIL; NITRAZEPAM; PAROXETINE; PROMETHAZINE; TIAPRIDE; TRAZODONE; TRIAZOLAM; VALPROIC ACID; ZOLPIDEM;

ADULT; ANOREXIA; ARTICLE; BRAIN ATROPHY; BRAIN VENTRICLE DILATATION; CASE REPORT; CLINICAL FEATURE; DEPRESSION; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELDERLY CARE; HUMAN; INSOMNIA; JAPANESE; LATERAL BRAIN VENTRICLE; MALE; OROFACIAL DYSKINESIA; PRIORITY JOURNAL; TARDIVE DYSKINESIA; TREATMENT FAILURE;

EID: 56849120785     PISSN: 13463500     EISSN: 14798301     Source Type: Journal    
DOI: 10.1111/j.1479-8301.2008.00245.x     Document Type: Article

References (10)

1. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry 2000; 161: 414-425.
2. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics? Mov Disord 2006; 21: 589-598.
3. Huang CC. Persistent tardive dyskinesia associated with amoxapine therapy. Am J Psychiatry 1986; 143: 1069-1070.
4. Caroff SN, Campbell EC, Havey J, Sullivan KA, Mann SC, Gallop R. Treatment of tardive dyskinesia with donepezil: A pilot study. J Clin Psychiatry 2001; 62: 772-775.
5. Inada T, Yagi G. Current topics in neuroleptic-induced extrapyramidal symptoms in Japan. Keio J Med 1996; 45: 95-99.
6. Kim JH, Jung HY, Kang UG et al. Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): A practical combined rating scale for drug-induced movement disorders. Mov Disord 2002; 17: 1354-1359.
7. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: Pathophysiology and mechanisms of induction. Can J Psychiatry 2005; 50: 541-547.
8. Miller R, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and l-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 1993; 34: 713-738.
9. Tammenmaa IA, Sailas E, McGrath JJ, Soares-Weiser K, Wahlbeck K. Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: A meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 1099-1107.
10. Caroff SN, Walker P, Campbell C et al. Treatment of tardive dyskinesia with galantamine: A randomized controlled crossover trial. J Clin Psychiatry 2007; 68: 410-415.